scholarly journals Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study

2017 ◽  
Vol 102 (7) ◽  
pp. 2416-2424 ◽  
Author(s):  
Tina Constantin ◽  
Vin Tangpricha ◽  
Reshma Shah ◽  
Nelson M. Oyesiku ◽  
Octavian C. Ioachimescu ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Controlled Study ◽  
Turnover Markers ◽  
Prospective Controlled Study

scholarly journals Response to Letter: “Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study”

2017 ◽  
Vol 102 (9) ◽  
pp. 3561-3562
Author(s):  
Tina Constantin ◽  
Vin Tangpricha ◽  
Reshma Shah ◽  
Nelson M Oyesiku ◽  
Octavian Ioachimescu ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Controlled Study ◽  
Turnover Markers ◽  
Prospective Controlled Study

scholarly journals A Double-Blind Placebo-Controlled Randomized Trial Evaluating the Effect of Polyphenol-Rich Herbal Congee on Bone Turnover Markers of the Perimenopausal and Menopausal Women

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Jintanaporn Wattanathorn ◽  
Woraluk Somboonporn ◽  
Sudarat Sungkamanee ◽  
Wipawee Thukummee ◽  
Supaporn Muchimapura
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Clinical Chemistry ◽  
Controlled Study ◽  
Total Phenolic ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Menopausal Women ◽  
Turnover Markers

Based on the benefit of polyphenolic compounds on osteoporosis, we hypothesized that the polyphenol-rich herbal congee containing the combined extract of Morus alba and Polygonum odoratum leaves should improve bone turnover markers in menopausal women. To test this hypothesis, a randomized double-blind placebo-controlled study was performed. A total of 45 menopausal participants were recruited in this study. They were randomly divided into placebo, D1, and D2 groups, respectively. The subjects in D1 and D2 groups must consume the congee containing the combined extract of M. alba and P. odoratum leaves at doses of 50 and 1500 mg/day, respectively. At the end of an 8-week consumption period, all subjects were determined serum bone markers including calcium, alkaline phosphatase, osteocalcin, and beta CTX. In addition, the hematological and blood clinical chemistry changes, and total phenolic content in the serum were also determined. The results showed that the menopausal women in D2 group increased serum alkaline phosphatase, osteocalcin, and total phenolic compounds content but decreased CTX level. Clinical safety assessment failed to show toxicity and adverse effects. Therefore, herbal congee containing the combined extract of M. alba and P. odoratum leaves is the potential functional food that can decrease the risk of osteoporosis.

scholarly journals Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days

2020 ◽  
Vol 106 (1) ◽  
pp. e171-e181
Author(s):  
Arthi Thirumalai ◽  
Fiona Yuen ◽  
John K Amory ◽  
Andrew N Hoofnagle ◽  
Ronald S Swerdloff ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Controlled Study ◽  
Type I ◽  
Healthy Men ◽  
Treatment Groups ◽  
Amino Terminal ◽  
Turnover Markers

Abstract Context Dimethandrolone undecanoate (DMAU) is being developed as a male contraceptive. Daily oral administration of DMAU, a potent androgen that is not aromatized, markedly suppresses serum testosterone (T) and estradiol (E2) in healthy men. E2 deficiency can increase bone resorption in men. Objective This work aimed to assess changes in bone turnover markers with DMAU administration in a 28-day study. Design A randomized, double-blind, placebo-controlled study was conducted. Setting This study took place at 2 academic medical centers. Participants Healthy men, age 18 to50 years (n = 81), participated. Intervention Men received 0, 100, 200, or 400 mg of oral DMAU for 28 days. Serum C-terminal telopeptide of type I collagen (CTX; bone resorption marker) and procollagen type I amino-terminal propeptide (P1NP; bone formation marker) were measured on days 1 and 28. Main Outcome Measures Changes in bone turnover markers and serum hormones over the treatment period were measured. Results On day 28, median serum T and E2 were markedly suppressed in all treatment groups vs placebo (P < .001 for both). Percentage change (%) in serum P1NP significantly differed across treatment groups (P = .007): Serum P1NP significantly increased in the 200 mg (5%, interquartile range [IQR] –7% to 27%) and 400 mg (22%, IQR –1% to 40%) groups relative to placebo (–8%, IQR –20% to 0%). Change (%) in serum CTX did not differ between groups (P = .09). Conclusions DMAU administration for 28 days to healthy men leads to marked suppression of serum T and E2, yet increases P1NP, a serum marker of bone formation. Longer-term studies of the potent androgen DMAU are warranted to determine its impact on bone health in men.

Postoperative Zoledronic Acid for Osteoporosis in Primary Hyperparathyroidism: a Randomized Placebo-controlled Study

2021 ◽  
Author(s):  
E M Ryhänen ◽  
A M Koski ◽  
Eliisa Löyttyniemi ◽  
M J Valimaki ◽  
Ulla Kiviniemi ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Zoledronic Acid ◽  
Femoral Neck ◽  
Primary Hyperparathyroidism ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Controlled Study ◽  
Mineral Density ◽  
Turnover Markers

Objective: In primary hyperparathyroidism (PHPT) with osteoporosis, bone mineral density (BMD) improves after parathyroidectomy. It is unclear whether combining surgery with postoperative bisphosphonate treatment can further improve bone health. Design: This randomized, placebo-controlled study compared the effects of surgery alone and surgery combined with zoledronic acid on bone metabolism in PHPT with osteoporosis. Methods: Fifty-six patients (f/m 47/9, mean age 68.4 years) with PHPT and osteoporosis were randomized 1–3 months after parathyroidectomy to receive a two-year treatment of zoledronic acid or placebo. Dual-energy X-ray absorptiometry (DXA) and bone turnover markers (N-terminal propeptide of type 1 procollagen, C-terminal telopeptide of type 1 collagen, and alkaline phosphatase) were measured annually during the 2-year follow-up. Results: Two years after parathyroidectomy, BMD was significantly higher in the zoledronic acid (ZOL) group compared with the placebo (PBO) group at the femoral neck (P = 0.045 for Z-score) and lumbar spine (P = 0.039 and 0.017 for T- and Z-scores, respectively). Bone turnover markers were significantly lower in the ZOL group (P < 0.001 for all markers). Of the 18 patients who had received bisphosphonates for >1 year before surgery, BMD improved significantly in the ZOL group both in the femoral neck and lumbar spine (N = 10; all P < 0.001–0.01) but in the PBO group only in the lumbar spine (N = 8, P = 0.03), (P= 0.08-0.95 for between-group changes). Conclusion: BMD increases after parathyroidectomy both with and without zoledronic acid but the increase is significantly higher with postoperative zoledronic acid.

Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma

2002 ◽  
Vol 20 (9) ◽  
pp. 2353-2359 ◽  
Author(s):  
Hans D. Menssen ◽  
Adriana Sakalová ◽  
Aurélie Fontana ◽  
Zuzana Herrmann ◽  
Christian Boewer ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Bone Pain ◽  
Stage Ii ◽  
Controlled Study ◽  
Treatment Groups ◽  
Skeletal Related Events ◽  
Turnover Markers ◽  
Post Hoc

PURPOSE: Bisphosphonates have been found to reduce the incidence of skeletal-related events (SREs) in patients with multiple myeloma. This is the first double-blind, randomized, placebo-controlled study to assess the efficacy of ibandronate, a third-generation amino-bisphosphonate, in preventing SREs in advanced-stage multiple myeloma patients. PATIENTS AND METHODS: Patients with multiple myeloma stage II or III were randomly assigned to receive either ibandronate 2 mg or placebo as a monthly intravenous (IV) bolus injection for 12 to 24 months in addition to conventional chemotherapy. SREs such as peripheral pathologic or vertebral fractures, hypercalcemia, severe bone pain, and bone radiotherapy or surgery were analyzed. Bone-turnover markers were also studied. Finally, post hoc analyses of bone morbidity and survival were performed. RESULTS: Ninety-nine patients per treatment group were assessable for efficacy analysis. The occurrence of SRE per patient year and the time to first SRE were not significantly different between the two treatment groups. In overall evaluation, no differences were found between the treatment groups regarding bone pain, analgesic drug use, quality of life, and median survival (33.1 v 28.2 months, respectively). Explorative post hoc analyses revealed that ibandronate patients with strongly suppressed bone-turnover markers (≥ 30% and ≥ 50% mean reduction of serum osteocalcin and urinary C-terminal telopeptides) developed significantly less bone morbidity. Ibandronate was tolerated well during as many as 25 therapy cycles. CONCLUSION: Monthly injections of ibandronate 2 mg IV neither reduced bone morbidity nor prolonged survival in the overall population of stage II/III multiple myeloma patients.

Sign in / Sign up

Export Citation Format

Share Document